Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413225 | 1.00 | VCAM1 (0.44) | VCAM1CYP4F2CYP4A11ACACBTRPV4 | |
| SCHEMBL2569992 | 0.84 | TRPV4 (0.52) | TRPV4MAOBMAOAMRGPRX4IDO1 | |
| SCHEMBL5066101 | 0.81 | MAOB (0.49) | TRPV4MAOBMAOASNCA | |
| SCHEMBL20489787 | 0.80 | LOXL2 (0.47) | VCAM1ACACBTRPV4MAOBMAOA | |
| SCHEMBL16954518 | 0.80 | VCAM1 (0.49) | VCAM1ACACBTRPV4MAOBMAOA | |
| SCHEMBL23550068 | 0.80 | VCAM1 (0.44) | VCAM1ACACBTRPV4MAOBMAOA | |
| SCHEMBL12188756 | 0.80 | CYP2A6 (0.47) | VCAM1ACACBTRPV4MAOBMAOA | |
| SCHEMBL18006944 | 0.79 | PYCR1 (0.46) | VCAM1ACACBPYCR1 | |
| SCHEMBL8364091 | 0.78 | SNCA (0.41) | TRPV4MAOBMAOASNCA | |
| SCHEMBL15716128 | 0.78 | MAOB (0.39) | TRPV4MAOBMAOAPYCR1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4537828-A2 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4200301-B1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230416202-A1 | Small Molecule Compounds and Compositions | TELO THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-11773122-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES. INC. (US) | 2023-10-03 | — | — | US | disclosed |
| EP-4247374-A1 | SMALL MOLECULE COMPOUNDS AND COMPOSITIONS | Telo Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-116710431-A | Small molecule compounds and compositions | 泰洛治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2010093845-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | EXELIXIS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2077262-A1 | IMINOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-07-08 | — | — | EP | disclosed |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2009-02-19 | — | — | US | disclosed |
| WO-2009005687-A1 | PURINE DERIVATIVES AND THEIR USE AS MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-4950673-A | 5-amino or substituted amino 1,2,3-triazoles | MERCK & CO., INC. (US) | 1990-08-21 | — | — | US | disclosed |
| EP-0151528-B1 | 5-(AMINO OR SUBSTITUTED AMINO)-1,2,3-TRIAZOLES | MERCK & CO. INC. (US) | 1990-07-04 | — | — | EP | disclosed |
| US-4816469-A | 5-Amino or substituted amino 1,2,3-triazoles | MERCK & CO., INC. (US) | 1989-03-28 | — | — | US | disclosed |
| US-4721791-A | 5-amino or substituted amino 1,2,3-triazoles | MERCK & CO., INC. (US) | 1988-01-26 | — | — | US | disclosed |
| EP-0151528-A2 | 5-(Amino or substituted amino)-1,2,3-triazoles | MERCK & CO. INC. (US) | 1985-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | VCAM1 4087/4885CYP4F2 33/4885CYP4A11 1190/4885 |
| US-20100016315-A1 | Iminopyridine Derivative and Use Thereof | ADRA1D, ADRB1, ADRB2 | VCAM1 459/4885CYP4F2 3209/4885CYP4A11 1829/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | VCAM1 1281/4885CYP4F2 2279/4885CYP4A11 2224/4885 |
| US-20230416202-A1 | Small Molecule Compounds and Compositions | TERT, TP53, EP300 | VCAM1 4055/4885CYP4F2 4563/4885CYP4A11 3707/4885 |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | VCAM1 1281/4885CYP4F2 2279/4885CYP4A11 2224/4885 |
| US-20090047249-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | VCAM1 709/4885CYP4F2 3150/4885CYP4A11 3181/4885 |
| US-11773122-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | VCAM1 1281/4885CYP4F2 2279/4885CYP4A11 2224/4885 |
| US-12473314-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | VCAM1 1281/4885CYP4F2 2279/4885CYP4A11 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.